Beryl Drugs Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 31.81 million compared to INR 20.63 million a year ago. Revenue was INR 32.19 million compared to INR 20.97 million a year ago. Net loss was INR 1.02 million compared to INR 1.7 million a year ago. Basic loss per share from continuing operations was INR 0.2 compared to INR 0.34 a year ago. Diluted loss per share from continuing operations was INR 0.2 compared to INR 0.34 a year ago.
For the nine months, sales was INR 111.35 million compared to INR 80.28 million a year ago. Revenue was INR 112.48 million compared to INR 86.06 million a year ago. Net loss was INR 1.85 million compared to net income of INR 1.22 million a year ago. Basic loss per share from continuing operations was INR 0.36 compared to basic earnings per share from continuing operations of INR 0.24 a year ago. Diluted loss per share from continuing operations was INR 0.36 compared to diluted earnings per share from continuing operations of INR 0.24 a year ago.